Verteporfin

Catalog No.S1786 Synonyms: CL 318952

Verteporfin  Chemical Structure

Molecular Weight(MW): 718.79

Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin.

Size Price Stock Quantity  
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 11 Publications

6 Customer Reviews

  • Verteporfin treatment inhibits proliferation and induces apoptosis of Tsc1-null cells in vivo. Mice were administered i.p. with vehicle or verteporfin at a dose of 100 mg/kg every other day for 10 d before sacrifice. Mice were sacrificed at 6 wk of age. Three independent experiments were performed and mice in different treatments were pooled for analysis. Percentage of Ki67 and αSMA double-positive cells in α-SMA+ mesenchymal lesions in the indicated kidneys. Immunofluorescence staining and counting were performed on three sagittal sections from different kidney regions for each mouse.

    J Exp Med 2014 211(11), 2249-63. Verteporfin purchased from Selleck.

    A representative immunostaining results of p-EGFR, p-ERK, YAP1, and cleavage caspase-3 in tumors of each group of nude mice.

    Theranostics, 2017, 7(5):1114-1132. Verteporfin purchased from Selleck.

  • Colony formation in H520 cells and H1581 cells that were with or without verteporfin

    Cancer Lett, 2018, 423:36-46. Verteporfin purchased from Selleck.

    The effects of ADR and Verteporfin on the growth of HCC xenograft derived from MHCC-97H cells (n = 5 for each group). Representative images of IHC staining of KI67 and cleaved caspase-3 in tumors. Scale bar: 100 μm.

    EBioMedicine, 2018, 35:142-154. Verteporfin purchased from Selleck.

  • The indicated cell lines were treated with control (Ctrl) or YAP-targeting siRNAs and growth assessed by XTT proliferation assays at the indicated time points. The mean and +SD are shown for three independent experiments. (Left panel, *, P < 0.05, significantly different from U87Rictor DMSO; Right panel, *, P < 0.05, significantly different from H4Rictor DMSO).

    J Biol Chem, 2015, 290(32): 19387-401 . Verteporfin purchased from Selleck.

    The levels of YAP, phospho-YAP (S127), and its downstream targeted molecules CTGF and CYR61 were analyzed by Western blotting after UM cells were exposed to verteporfin for 24 hours.

    Am J Cancer Res, 2016, 6(12):2816-2830.. Verteporfin purchased from Selleck.

Purity & Quality Control

Choose Selective VDA Inhibitors

Biological Activity

Description Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin.
Targets
VDA [1]
(Endothelial cells)
YAP/TEAD interaction [3]
In vitro

Verteporfin is about four times more efficient in absorbing light at wavelengths that penetrate tissues best (i.e., around 700 nm) and thus provides a much higher cytotoxic effect than hematoporphyrin (10 times more in human adherent cell lines). Verteporfin is lipophilic and is more readily taken up by malignant or activated cells, compared with normal or resting cells. Verteporfin binds with LDL to form a complex, which is then taken up into proliferating cells (e.g., neovascular endothelial cells) probably via LDL receptors and endocytosis. Verteporfin therapy achieves complete angiographic occlusion of the neovascular compartment by thrombosis of vascular channels, following selective endothelial damage. Verteporfin therapy selectively induces reproducible and isolated choriocapillary occlusion without alteration of overlying photoreceptors or ganglion cells, as shown by light and electron microscopy. [1] Verteporfin conbined with light rapidly exhibits apoptotic changes reflected by caspase-3 and caspase-9 activation and PARP cleavage in HL-60 cells, changes that are blocked by the general caspase inhibitor ZVAD.fmk. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL-60 NXj1UXFGTnWwY4Tpc44h[XO|YYm= NVLUSZduhjFyMDDu[{9uVA>? NV:5RYNLTE2VTx?= NUTufWExcW6lcnXhd4V{KESQQTDmdoFodWWwdHH0bY9vKGyndnXsdy=> NEPmdmsyODZyN{exNC=>
HL-60 NIf5S5hkgXSxdH;4bYNqfHliYYPzZZk> NH;lV3V,OTByIH7nM41N NIrI[VNFVVOR MXrpcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MVSxNFYxPzdzMB?=
Jurkat NXzKdHdYSXCxcITvd4l{KGG|c3H5 NIS0bYN,OjhyIH7N MUHEUXNQ MkTabY5lfWOnczDhJGJkdC1{LXTldIVv\GWwdDDhdI9xfG:|aYO= NGHqT5kyOTJ2NUSxOS=>
RIF-1 NHfDWmtHfW6ldHnvckBie3OjeR?= MWOxJO69\y:vbB?= MVXEUXNQ NIDvdmNl\WO{ZXHz[ZMhd3i7Z3XuJINwdnO3bYD0bY9v NH\mUHoyOjZzNUexPC=>
RIF-1 MYrjfZRwfG:6aXPpeJkh[XO|YYm= NIjoZVMyKM7:Zz;tcC=> MXjEUXNQ Ml3p[IVkemWjc3WgeI8hOjBiwsGgOUUh[2WubDDzeZJ3cX[jbB?= MUmxNlYyPTdzOB?=
SVEC4-10 NFroS4hHfW6ldHnvckBie3OjeR?= NWLTUGlKOjByIH7nM41t Ml\aSG1UVw>? M2D0Oolv\HWlZYOgcYlkem:2dXL1cIUh\GWyb3z5cYVzcXqjdHnvci=> M2\MTFE3PDZ5MUC2
SVEC4-10 NWjaV3JvTnWwY4Tpc44h[XO|YYm= NWTYXW1WOjByIH7nM41t M{HpUGROW09? M4\lO4lv\HWlZYOgd5Rz\XO|IHHjeIlvKG[rYnXyJIZwem2jdHnvci=> MmTvNVY1PjdzME[=
ARPE-19 NXHwUVlL[3m2b4TvfIlkcXS7IHHzd4F6 MXv+NE4yKM7:Zz;tcC=> M1jKUGROW09? M3rrR5Npd3e|IHGg[I9{\S2mZYDlcoRmdnRidH;4bYNqfHl? MoXmNVY6QDd7MEW=
ARPE-19 MVPGeY5kfGmxbjDhd5NigQ>? MlXvNE4xOSEQvHevcYw> MW\EUXNQ MoHnbY5kemWjc3XzJHZGT0ZiYX7kJJJm\HWlZYOgVGVFTiCneIDy[ZN{cW:w MkPsNVY6QDd7MEW=
Y-79 MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MlrFglEh|rypL33s MmPzSG1UVw>? Mnzz[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?= NYrsXFJTOTh3N{m3OlQ>
WERI-Rb1 MkPZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmfiglEh|rypL33s M1PmPGROW09? MXfk[YNz\WG|ZYOgdoV1cW6xYnzhd5RwdWFiY3XscEBxem:uaX\ldoF1cW:w NVLFboR4OTh3N{m3OlQ>
RB247C3 NFnkSHdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVf+NUDPxGdxbXy= NWfLOpIyTE2VTx?= NYGzUIcy\GWlcnXhd4V{KHKndHnuc4Jt[XO2b33hJINmdGxicILvcIln\XKjdHnvci=> M3ribFE5PTd7N{[0
RB355 MlG1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NX\nclFNhjFizsznM41t NYn2fpFrTE2VTx?= NFvFcVJl\WO{ZXHz[ZMhemW2aX7vZoxie3SxbXGgZ4VtdCCycn;sbYZmemG2aX;u NED0XpgyQDV5OUe2OC=>
RB383 NWDMUlFXT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2DEVp4yKM7:Zz;tcC=> MoL2SG1UVw>? MnjB[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?= MYSxPFU4QTd4NB?=
hFibro MmDqZ5l1d3SxeHnjbZR6KGG|c3H5 MY[wMlUhyrWpL33s MUXEUXNQ M1X0RYRm[3KnYYPld{B3cWGkaXzpeJkh[nliOE[sOUU> M1LPZ|I{PDRzMUG0
pTMC M2e5RoN6fG:2b4jpZ4l1gSCjc4PhfS=> Mo[zNE42KML3Zz;tcC=> M1XXXGROW09? NWLRcJRz\GWlcnXhd4V{KH[rYXLpcIl1gSCkeTC5Nk46LQ>? MXiyN|Q1OTFzNB?=
hTMC M3LEOoN6fG:2b4jpZ4l1gSCjc4PhfS=> MV6wMlUhyrWpL33s NF24SZhFVVOR MXnk[YNz\WG|ZYOgeoli[mmuaYT5JIJ6KDh6Lkml MmqyNlM1PDFzMUS=
ARPE-19 MUPjfZRwfG:6aXPpeJkh[XO|YYm= M1fmS|AvPSEEtXevcYw> NUK4b2l{TE2VTx?= NV35cFdT\GWlcnXhd4V{KH[rYXLpcIl1gSCkeTC1OU42LQ>? NIHS[GQzOzR2MUGxOC=>
Panc-1 MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVWxNEDPxE1? NYraU2xmTE2VTx?= MoHtbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u M1\mZ|I1ODZ7ME[5
MIA PaCa-2 M3PWW2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlLaNVAh|ryP MmLvSG1UVw>? MYnpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= MojVNlQxPjlyNkm=
BxPC-3 MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M13YeFExKM7:TR?= M3K0Z2ROW09? NIDQ[I1qdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[2:vcHzleIVtgQ>? NYi4R2U4OjRyNkmwOlk>
SU86.86 NF\TRnBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmOzNVAh|ryP M1fQfmROW09? MUDpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gZ49ueGyndHXsfS=> NIjPR2gzPDB4OUC2PS=>
MCF-7 MmnyRZV1d3CqYXf5JIF{e2G7 NHTTbnEyOCEQvF2= NHLscVVFVVOR MlzSbY5pcWKrdIOg[4Vu[2m2YXLpcoUucW6mdXPl[EBifXSxcHjh[5k> MX[yOFA3QTB4OR?=
WERI MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4fJc54yOCEQvHevcYw> MofGSG1UVw>? MoL1bY5pcWKrdIOg[5Jwf3SqIH;mJJJmfGmwb3LsZZN1d22jIHPlcIx{ M3jwbFI1QDN5MUSy
WERI MXvGeY5kfGmxbjDhd5NigQ>? NXjJTWxVhjFyIN88[{9udA>? NIPYWGpFVVOR MnHFZoxw[2u|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44> MkLUNlQ5OzdzNEK=
Y-79 M2\PTmZ2dmO2aX;uJIF{e2G7 M2TOW54yOCEQvHevcYw> M2nCXmROW09? M1jCfoJtd2OtczDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9v NVruXGpHOjR6M{exOFI>
Y-79 MmfGSpVv[3Srb36gZZN{[Xl? MoTmglExKM7:Zz;tcC=> NEnJXWNFVVOR MoPzZYZn\WO2czDZRXAuXEWDRDDwdo91dy2xbnPv[4Vv\SCyYYToe4F6 M{DNR|I1QDN5MUSy
Y-79 M2rROGZ2dmO2aX;uJIF{e2G7 NYrUWWsyhjFyIN88[{9udA>? M33EeGROW09? NUPOPZl2\G:5bj3y[Yd2dGG2ZYOgdIx2emmyb4TlcoN6KG2jcnvldkBQS1RvNB?= MY[yOFg{PzF2Mh?=

... Click to View More Cell Line Experimental Data

In vivo Verteporfin can be used for angiographic visualization of choroidal vessels and CNV, which demonstrates that the photosensitizer accumulates rapidly in experimental CNV in monkeys. Verteporfin accumulates rapidly in the established vasculature of the choroid, RPE, and photoreceptors of rabbit eyes. Verteporfin reaches maximal tissue levels within 3 hours of intravenous injection, followed by a rapid decline within 24 hours in mice. Verteporfin is metabolized to a less active form in vivo and is cleared very rapidly, predominantly in the feces and a very small proportion excreted in urine. Verteporfin therapy effectively and selectively prevents fluorescein dye leakage from experimentally induced CNV in monkeys. [1]

Protocol

Solubility (25°C)

In vitro DMSO 100 mg/mL (139.12 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 718.79
Formula

C41H42N4O8

CAS No. 129497-78-5
Storage powder
in solvent
Synonyms CL 318952

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03067051 Recruiting Recurrent Prostate Cancer SpectraCure AB March 21 2017 Phase 1
NCT03067051 Recruiting Recurrent Prostate Cancer SpectraCure AB March 21 2017 Phase 1
NCT03033225 Recruiting Pancreatic Cancer Non-Resectable Mayo Clinic January 5 2017 Phase 2
NCT03033225 Recruiting Pancreatic Cancer Non-Resectable Mayo Clinic January 5 2017 Phase 2
NCT02939274 Recruiting Metastatic Breast Cancer Rogers Sciences Inc. October 2016 Phase 2
NCT02939274 Recruiting Metastatic Breast Cancer Rogers Sciences Inc. October 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VDA Signaling Pathway Map

Related VDA Products0

Tags: buy Verteporfin | Verteporfin ic50 | Verteporfin price | Verteporfin cost | Verteporfin solubility dmso | Verteporfin purchase | Verteporfin manufacturer | Verteporfin research buy | Verteporfin order | Verteporfin mouse | Verteporfin chemical structure | Verteporfin mw | Verteporfin molecular weight | Verteporfin datasheet | Verteporfin supplier | Verteporfin in vitro | Verteporfin cell line | Verteporfin concentration | Verteporfin nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID